Aaron Mangold is a Dermatology physician affiliated with WinnMed. OpenAlex indexes 254 publications with 2,007 citations (h-index 25); ClinicalTrials.gov lists 9 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
13400 E Shea Blvd
Scottsdale, AZ 852595452
Telephone
480-301-8000Provider last certified this registry record 8 Sept 2020.
Clinical trials
- Deucravacitinib (BMS-986165) for Pityriasis Rubra Pilaris
Sponsor: Mayo Clinic
- A Study of Deucravacitinib to Treat LPP and FFA
Sponsor: Mayo Clinic
- Education for Prevention of Melanoma in Hispanic Populations
Sponsor: Mayo Clinic
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
18 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Regeneron Pharmaceuticals, Inc.Program year202526 payments$45,220openpaymentsdata.cms.gov ↗
- BioCryst Pharmaceuticals, Inc.Program year20253 payments$12,902openpaymentsdata.cms.gov ↗
- LEO Pharma ASProgram year20252 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Dermatology
20%Corticosteroid17.6%Triamcinolone Acetonide53%Triamcinolone acetonide47%Part D + Part B≥83 patientsInterleukin-4 Receptor alpha Antagonist2.5%Dupixent Syringe100%Part D<11 patientsAnti-infectives
17.1%Azole Antifungal7.8%Fluconazole51%Ketoconazole49%Part D≥20 patientsHerpesvirus Nucleoside Analog DNA Polymerase Inhibitor3.7%Valacyclovir100%Part D≥22 patients+ 3 more classes in this area
Cancer & immunology
15.6%Folate Analog Metabolic Inhibitor8.2%Methotrexate100%Part D≥32 patientsPorphyrin Precursor2.5%Aminolevulinic acid hcl100%Part B, office-administered≥30 patients+ 4 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- riSCC: A personalized risk model for the development of poor outcomes in cutaneous squamous cell carcinoma
Journal of the American Academy of Dermatology
2025
Similar KOLs
Other experts from the same institution or the same specialty.
Mayank Sardana, MD
WinnMed
Rakesh Suri, MD
WinnMed
Jorge Rakela, MD
WinnMed
Hugo Vargas, MD
WinnMed
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”